45
Participants
Start Date
May 31, 2007
Primary Completion Date
January 31, 2008
Study Completion Date
April 30, 2011
Doxorubicin
Cyclophosphamide
Paclitaxel
Sorafenib
Peninsula Cancer Institute, Newport News
Integrated Community Oncology Network, Jacksonville
Florida Hospital Cancer Institute, Orlando
Tennessee Oncology, PLLC, Nashville
Chattanooga Oncology Hematology Associates, Chattanooga
Consultants in Blood Disorders and Cancer, Louisville
Grand Rapids Clinical Oncology Program, Grand Rapids
Methodist Cancer Center, Omaha
Collaborators (1)
Bayer
INDUSTRY
SCRI Development Innovations, LLC
OTHER